Search results

Selected filters:

North America
Valuation

Article type

Topic

Sector

Jurisdictions

208 results found for your search

Sort options
09 October 2019

IBM has the world's most valuable patent portfolio, new analysis claims

Samsung, Canon, Microsoft and Bosch round-out the top five who, between them, are said to own assets worth well in excess of $35 billion

04 October 2019

The new China dynamic, pool progress and more from our Patent Licensing event

The big takeaways from a day of deal-making discussions in the heart of Silicon Valley

27 September 2019

Before IBM arrived, building a patent deterrent meant plenty of deals for Red Hat

In an exclusive interview, the company's IP head reveals that in the run-up to its acquisition by Big Blue the open source leader went shopping at a range of companies include AT&T, Huawei and Panasonic

23 September 2019

Nanjing judge sets Chinese SEP rate in dispute between Conversant and Huawei

Chinese court has had its say on royalties - and it looks like the telecoms giant has got exactly what it was looking for

30 August 2019

Amgen’s $13.4 billion Otezla purchase shows, once more, the direct financial value of IP in the life sciences space

The Californian company cites US patent protection until 2028 as a key driver of the psoriasis drug acquisition, but antitrust concerns remain

26 August 2019

Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last

09 August 2019

NASA’s portfolio is the definition of lean and mean

The iconic agency – which celebrated the 50th anniversary of putting the first man on the moon last month - is highly selective with the innovations it patents and constantly reviews holdings to eliminate deadweight

01 August 2019

Expect Pfizer to focus on more oncology opportunities following off-patent drug purge

After $12 billion Upjohn deal with Mylan, CEO Bourla says company is on the hunt for early- and mid-stage cancer assets

23 July 2019

It's security, stupid - why it's time to see the wood from the trees in the FTC's case against Qualcomm

If the US chipmaker’s recent court defeat stands then the US risks ceding to China a central role in the development of 5G and future wireless technology

19 July 2019

Alphabet is trimming down its portfolio - but only after sustained growth  

The tech giant saw a steep drop in the number of US patents granted in 2018 after having spent years building its portfolio organically and through strategic acquisitions

16 July 2019

Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector

New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline

05 July 2019

Get ready for the first CRISPR patent pool

In an exclusive interview, MPEG LA’s Kristin Neuman says that a pool is on its way despite the UCal v Broad stand-off and talks about the future of licensing in biotech’s ‘golden age’

02 July 2019

AbbVie’s Allergan play designed to mitigate Humira patent cliff

The $63 billion purchase is designed to mitigate the effects of losing the exclusive rights to the world’s best selling drug

29 June 2019

Faraday Future’s patent portfolio may be small, but it packs a punch

The struggling electric vehicle start-up has invested significantly in building its assets, and while it trails behind competitors it has a number of holdings in valuable areas which may come in handy

28 June 2019

Politics, money could temper Chinese interest in Intel auction

A few years ago, it might have been different. But political, legal and economic uncertainty may combine to keep firms like Huawei and ZTE out of the running for Intel’s wireless IP